Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (atria) study, ):516?21. 2. Go AS, pp.2370-2375, 2001. ,
Epidemiologic Features of Chronic Atrial Fibrillation Epidemiology and natural history of atrial fibrillation: clinical implications Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study), 1018?22. 4. Chugh SS,371?8. 5. Furberg CD, pp.236-277, 1982. ,
Increasing Prevalence of Atrial Fibrillation and Flutter in the United States, The American Journal of Cardiology, vol.104, issue.11, pp.1534-1543, 2009. ,
DOI : 10.1016/j.amjcard.2009.07.022
Secular Trends in Incidence of Atrial Fibrillation in Olmsted County, Minnesota, and Implications on the Projections for Future Prevalence. Circulation, pp.119-144, 1980. ,
Atrial Fibrillation: Current Concepts, Int J Health Sci. janv, vol.2, issue.1, pp.85-90, 2008. ,
Classification of atrial fibrillation, Am J Cardiol. 16 oct, vol.82, issue.8A, 1998. ,
Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation. 15 mars, vol.123, issue.10, pp.269-367, 2006. ,
Characterization of Different Subsets of Atrial Fibrillation in General Practice in France : The ALFA Study, Circulation, vol.99, issue.23, pp.3028-3063, 1999. ,
DOI : 10.1161/01.CIR.99.23.3028
2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association, Eur Heart J. 1 nov, vol.33, issue.21, pp.2719-2766, 2012. ,
Long-?Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation A 30-?Year Follow-?Up Study. Circulation, pp.3050-3056, 2007. ,
Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on Atrial Fibrillation, European Heart Journal, vol.29, issue.9, pp.1181-1190, 2008. ,
DOI : 10.1093/eurheartj/ehn139
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study, Stroke, vol.22, issue.8, pp.983-991, 1991. ,
DOI : 10.1161/01.STR.22.8.983
Supraventricular tachyarrhythmia as a cause of sudden cardiac arrest, Journal of Interventional Cardiac Electrophysiology, vol.99, issue.2, pp.97-104, 2006. ,
DOI : 10.1007/s10840-006-9042-4
Shedding new light on the pathophysiology of conversion of paroxysmal atrial fibrillation into persistent atrial fibrillation, American Heart Journal, vol.154, issue.5, pp.801-805, 2007. ,
DOI : 10.1016/j.ahj.2007.07.017
Cardioembolic stroke: an update, The Lancet Neurology, vol.2, issue.3, pp.177-88, 2003. ,
DOI : 10.1016/S1474-4422(03)00324-7
Outcome parameters for trials in atrial fibrillation: executive summary: Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA), European Heart Journal, vol.28, issue.22, pp.2803-2820, 2007. ,
DOI : 10.1093/eurheartj/ehm358
Tachycardia-Induced Atrial Myopathy:., Journal of Cardiovascular Electrophysiology, vol.95, issue.9, pp.1065-74, 1997. ,
DOI : 10.1016/0735-1097(94)00452-V
Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials, Journal of the American College of Cardiology, vol.32, issue.3, pp.695-703, 1998. ,
DOI : 10.1016/S0735-1097(98)00297-6
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation, New England Journal of Medicine, vol.349, issue.11, pp.1019-1045, 2003. ,
DOI : 10.1056/NEJMoa022913
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation, Annals of Internal Medicine, vol.131, issue.7, pp.492-501, 1999. ,
DOI : 10.7326/0003-4819-131-7-199910050-00003
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial, Lancet. 10 juin, vol.367, issue.9526, pp.1903-1915, 2006. ,
Oral Anticoagulants vs Aspirin in Nonvalvular Atrial Fibrillation, JAMA, vol.288, issue.19, pp.2441-2449, 2002. ,
DOI : 10.1001/jama.288.19.2441
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial, The Lancet, vol.370, issue.9586, pp.493-503, 2007. ,
DOI : 10.1016/S0140-6736(07)61233-1
Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009. ,
DOI : 10.1056/NEJMoa0905561
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, New England Journal of Medicine, vol.365, issue.10, pp.883-91, 2011. ,
DOI : 10.1056/NEJMoa1009638
URL : https://hal.archives-ouvertes.fr/hal-01038111
Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation, The American Journal of Cardiology, vol.86, issue.8, pp.852-857, 2000. ,
DOI : 10.1016/S0002-9149(00)01105-X
Validation of Clinical Classification Schemes for Predicting Stroke, JAMA, vol.285, issue.22, pp.2864-70, 2001. ,
DOI : 10.1001/jama.285.22.2864
Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter, Canadian Journal of Cardiology, vol.27, issue.1, pp.74-90, 2011. ,
DOI : 10.1016/j.cjca.2010.11.007
Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin, Circulation, vol.110, issue.16, pp.2287-92, 2004. ,
DOI : 10.1161/01.CIR.0000145172.55640.93
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) Pilot Study, American Heart Journal, vol.148, issue.1, p.180, 2004. ,
DOI : 10.1016/j.ahj.2004.02.008
The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: Role of incorporating PR prolongation, Atherosclerosis, vol.237, issue.2, pp.504-517, 2014. ,
DOI : 10.1016/j.atherosclerosis.2014.08.026
A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation, Chest, vol.138, issue.5, pp.1093-100, 2010. ,
DOI : 10.1378/chest.10-0134
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range, Chest, vol.119, issue.1, pp.8-21, 2001. ,
DOI : 10.1378/chest.119.1_suppl.8S
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I, Journal of Thrombosis and Haemostasis, vol.21, issue.Suppl., pp.1573-80, 2004. ,
DOI : 10.1111/j.1538-7836.2004.00890.x
Scheen AJ [b2] (analytic) LE MÉDICAMENT DU MOIS: Dabigatran étexilate (Pradaxa[sub]®[/sub]): anticoagulant oral, inhibiteur direct sélectif de la thrombine (French), Dabigatran Etixilate Pradaxasub®sub ORAL ANTICOAGULANT Act DIRECT Sel Inhib THROMBIN Engl. cover date, vol.65, issue.10, pp.588-92, 2010. ,
Pradaxa[sub]®[/sub] ([sup]D[/sup]abigatran [sup]E[/sup]texilate) et chirurgie orthopédique: pourquoi, pour qui et comment ? ,
Sommaire des motifs de décision (SMD) : Pradax -? 2008 -? Santé Canada [Internet], Disponible sur, 2008. ,
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement, Thrombosis Research, vol.127, issue.5, pp.457-65, 2011. ,
DOI : 10.1016/j.thromres.2011.01.001
Des anciens aux nouveaux anticoagulants : le rôle du biologiste 1 sept, Ann Biol Clin, vol.67, issue.5, pp.525-559, 2009. ,
Chevalet P [b1] (analytic), Piloquet F-?X [b1] (analytic), Berrut G [b1] (analytic), De Decker L [b1] (analytic). Caractéristiques générales des nouveaux anticoagulants oraux (French), Gen Charact New Oral Anticoagulants Engl. cover date, vol.11, issue.SUP1, pp.4-9, 2013. ,
A New Generation of Oral Direct Anticoagulants, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.32, issue.3, pp.569-74, 2012. ,
DOI : 10.1161/ATVBAHA.111.242834
Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors, American Journal of Hematology, vol.171, issue.Suppl 1, pp.141-146, 2012. ,
DOI : 10.1002/ajh.23202
Reversal of antithrombotic agents, American Journal of Hematology, vol.129, issue.Suppl 2, pp.119-145, 2012. ,
DOI : 10.1002/ajh.23165
Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model, Critical Care, vol.18, issue.1, p.27, 2014. ,
DOI : 10.1093/bja/aes502
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4, pp.446-51, 2013. ,
DOI : 10.1038/nm.3102